Compare General Dynamics Corporation (GD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? General Dynamics Corporation trades at $331.32 (market cap $89.26B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and General Dynamics Corporation pays a 1.93% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GD | VRTX | |
|---|---|---|
Market Cap | $89.26B | $128.16B |
Volume | 1,496,273 | 806,603 |
Sector | Industrials | Health |
52-Week High | $395.97 | $557.96 |
52-Week Low | $312.53 | $407.37 |
Typical Hold Time | 85 Days | 120 Days |
Enterprise Value | $94.40B | $122.29B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $326.63, down 1.42% with bearish technical signals despite strong fundamentals. The defense contractor shows consistent revenue growth to $52.55B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with a $420.57 price target, supported by robust Pentagon spending and dividend reliability. Technical indicators show oversold conditions with RSI at 11.03, though moving averages signal bearish momentum.
GD presents a compelling value opportunity with attractive valuation metrics (P/E 19.92) and strong cash flow generation. Key risks include defense budget volatility and execution challenges, but the company's record backlog and dividend stability provide downside protection. The stock offers 28% upside to consensus targets with defensive characteristics suitable for long-term investors.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
